Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis - Harrison, S A; Abdelmalek, M F; Caldwell, S; GS-US-321-0105 and GS-US-321-0106 Investigators (Gastroenterology, 2018)